3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
23
Active not recruiting
16
Completed
3
Terminated
1
Suspended
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
pembrolizumab
111
Carboplatin
45
Nivolumab
41
Paclitaxel
34
Cyclophosphamide
32
Cisplatin
32
Gemcitabine
30
atezolizumab
27
Specimen Handling
25
venetoclax
24
Magnetic Resonance Spectroscopy
24
Pemetrexed
23
fludarabine
22
Biopsy
22
Radiotherapy
21
Ipilimumab
21
Docetaxel
21
Bevacizumab
21
Azacitidine
21
Radiosurgery
18
durvalumab
17
Fluorouracil
17
Dexamethasone
17
Cetuximab
16
fludarabine phosphate
14
Trastuzumab
14
Leucovorin
13
Cytarabine
13
tislelizumab
12
olaparib
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
lutetium Lu 177 dotatate
×
1 year
×
Clear all
NCT05987176
2026-01-14
NELMAS
Imperial College London
Phase 2
Terminated
1 enrolled